ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Ring Therapeutics raises $50 million for anellovirus gene therapies

by Ryan Cross
January 3, 2020 | APPEARED IN VOLUME 98, ISSUE 1

 

Flagship Pioneering is committing $50 million in funding to Ring Therapeutics, a start-up it founded in 2017 to discover and develop virus-based gene therapies. Nearly all existing gene therapies rely on adeno-associated viruses or lentiviruses to deliver therapeutic genes in the body. Ring hopes to overcome limitations associated with these delivery vessels—such as immune reactions—by scanning the human body for viruses that live peacefully alongside our immune systems. Ring is focused on anelloviruses, a class of these commensal viruses.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment